Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Martin S. Maron(Tufts Medical Center), Theodore P. Abraham(University of California, San Francisco), Artur Oręziak(Institute of Cardiology), Stephen B. Heitner(Baim Institute for Clinical Research), John A. Spertus(Spertus Institute for Jewish Learning and Leadership), Michelle Michels(Erasmus MC), Michael Arad(Tel Aviv University), Gregory D. Lewis(Massachusetts General Hospital), Iacopo Olivotto, Amy Wohltman(Baim Institute for Clinical Research), Hugh Watkins(Centre for Human Genetics), Nuno Cardim, Anjali Owens(University of Pennsylvania), Caroline Coats(Baim Institute for Clinical Research), James L. Januzzi(Harvard University), Brian Claggett(Brigham and Women's Hospital), Scott D. Solomon(Brigham and Women's Hospital), Albert Hagège, Matthew M.Y. Lee(Baim Institute for Clinical Research), Pablo García‐Pavía(Universidad Francisco de Vitoria), Daniel Jacoby(Baim Institute for Clinical Research), Ahmad Masri(Oregon Health & Science University), Fady I. Malik(Baim Institute for Clinical Research), Stuart Kupfer(Baim Institute for Clinical Research), Lisa Meng(Baim Institute for Clinical Research), Lubna Choudhury(Baim Institute for Clinical Research), Michael E. Nassif(Saint Luke's Hospital), Marion van Sinttruije(Baim Institute for Clinical Research), Changsheng Ma(Baim Institute for Clinical Research), Josef Veselka(Baim Institute for Clinical Research), Jacob Tfelt‐Hansen(Copenhagen University Hospital), Hans‐Dirk Düngen(Baim Institute for Clinical Research), Roberto Barriales‐Villa
Cited by 277
Related Papers
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2022|2.6k